Relay Therapeutics Stock Surges 15% on Bullish Analyst Note
Relay Therapeutics (RLAY) saw its shares jump nearly 15% this week, fueled by Guggenheim Securities' initiation of coverage with a buy rating and a $15 price target. Analyst Brad Canino highlighted the biotech's promising late-stage breast cancer drug RLY-2608, citing its clean safety profile and potential in treating vascular malformations.
The company's stock is currently trading below its cash position, attracting bargain hunters. Relay's second-quarter improvements and strong clinical trial progress further bolster Optimism about its future prospects.